Weighted Average Number of Shares Outstanding, Basic of Ernexa Therapeutics Inc. from 30 Jun 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Ernexa Therapeutics Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 30 Jun 2010 to 30 Sep 2025.
  • Ernexa Therapeutics Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 30 Sep 2025 was 8,226,000, a 2179% increase year-over-year.
  • Ernexa Therapeutics Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 13,647,000, a 157% increase from 2023.
  • Ernexa Therapeutics Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 5,314,000, a 74% increase from 2022.
  • Ernexa Therapeutics Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 3,051,000, a 41% increase from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Ernexa Therapeutics Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 8,226,000 +7,865,000 +2179% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 5,179,000 +4,818,000 +1335% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 53,361,000 +47,951,000 +886% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 13,647,000 +8,333,000 +157% 01 Oct 2024 31 Dec 2024 10-K 12 Mar 2025 2024 FY
Q3 2024 361,000 -5,049,000 -93% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025 2025 Q3
Q2 2024 361,000 -4,942,000 -93% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 5,410,000 +283,000 +5.5% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 5,314,000 +2,263,000 +74% 01 Oct 2023 31 Dec 2023 10-K 12 Mar 2025 2024 FY
Q3 2023 5,410,000 +2,469,000 +84% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 5,303,000 +2,363,000 +80% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 5,127,000 +2,446,000 +91% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 3,051,000 +886,000 +41% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 2,941,000 +414,000 +16% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 2,940,000 -39,508,000 -93% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 2,681,000 +2,653,201 +9544% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 2,165,000 -15,423,000 -88% 01 Oct 2021 31 Dec 2021 10-K 20 Mar 2023 2022 FY
Q3 2021 2,527,000 -15,099,806 -86% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 42,448,000 +24,864,511 +141% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 27,799 -17,474,014 -100% 01 Jan 2021 31 Mar 2021 10-Q 01 Jul 2022 2022 Q1
Q4 2020 17,588,000 01 Oct 2020 31 Dec 2020 10-K/A 01 Jul 2022 2021 FY
Q3 2020 17,626,806 +14,752,806 +513% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 17,583,489 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021 2021 Q2
Q1 2020 17,501,813 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q3 2019 2,874,000 +17,000 +0.6% 01 Jul 2019 30 Sep 2019 10-Q 01 Nov 2019 2019 Q3
Q3 2018 2,857,000 +352,000 +14% 01 Jul 2018 30 Sep 2018 10-Q 01 Nov 2019 2019 Q3
Q3 2017 2,505,000 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2018 Q3
Q3 2013 71,202 +326 +0.46% 01 Jul 2013 30 Sep 2013 10-Q 14 Nov 2013 2013 Q3
Q4 2012 70,594 01 Oct 2012 31 Dec 2012 10-K 29 Mar 2013 2012 FY
Q3 2012 70,876 -60,333,124 -100% 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013 2013 Q3
Q2 2012 70,506 +10,118 +17% 01 Apr 2012 30 Jun 2012 10-K 29 Mar 2013 2012 FY
Q1 2012 64,519 01 Jan 2012 31 Mar 2012 10-K 29 Mar 2013 2012 FY
Q3 2011 60,404,000 +195,000 +0.32% 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2011 2011 Q3
Q2 2011 60,388 +200 +0.33% 01 Apr 2011 30 Jun 2011 10-Q 12 Aug 2011 2011 Q2
Q3 2010 60,209,000 01 Jul 2010 30 Sep 2010 10-Q 14 Nov 2011 2011 Q3
Q2 2010 60,188 01 Apr 2010 30 Jun 2010 10-Q 12 Aug 2011 2011 Q2

Ernexa Therapeutics Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 13,647,000 +8,333,000 +157% 01 Jan 2024 31 Dec 2024 10-K 12 Mar 2025 2024 FY
2023 5,314,000 +2,263,000 +74% 01 Jan 2023 31 Dec 2023 10-K 12 Mar 2025 2024 FY
2022 3,051,000 +886,000 +41% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 2,165,000 -15,423,000 -88% 01 Jan 2021 31 Dec 2021 10-K 20 Mar 2023 2022 FY
2020 17,588,000 01 Jan 2020 31 Dec 2020 10-K/A 01 Jul 2022 2021 FY
2012 69,040 -60,332,960 -100% 01 Jan 2012 31 Dec 2012 10-K 29 Mar 2013 2012 FY
2011 60,402,000 +268,000 +0.45% 01 Jan 2011 31 Dec 2011 10-K 30 Mar 2012 2011 FY
2010 60,134,000 01 Jan 2010 31 Dec 2010 10-K 30 Mar 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.